Bladder Cancer (Testing)

Clinic Adds Breakthrough Test To Manage Cancer

Published in Cancer Weekly, May 12th, 1997

The Cleveland Clinic Foundation, Cleveland, Ohio, announced that it has added a quantitative, non-invasive test using breakthrough technology to the management protocol for bladder cancer patients.

The NMP 22 Test Kit, manufactured by Matritech, Inc., Newton, Massachusetts, uses a proprietary monoclonal antibody assay to measure the levels of a nuclear matrix protein (NMP), NMP22, in the urine. The test is the only, quantitative, non-invasive urine test for transitional cell carcinoma (TCC), the type of cancer responsible for 90 percent of bladder cancers.

The Cleveland Clinic will use this bladder cancer immunoassay test exclusively for two years. ...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1997-05-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry